In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...
Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER ...
Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...
The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a once-daily tablet for some patients with locally advanced or metastatic oestrogen receptor (ER)-positive, HER2-negative ...
A Prescription Drug User Fee Act target date of June 5, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Breast cancer remains the most common cause of cancer-associated death among women and is responsible for nearly 15% of all new cancer cases each year in the United States 1. This disease presents as ...
Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, the ...
Orserdu (elacestrant) is a targeted hormonal therapy for breast cancer. Unlike chemotherapy, which can harm both healthy and cancer cells, targeted therapy aims at specific proteins in the cancer ...
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results